AnaptysBio's CFO to Present at H.C. Wainwright Investment Conference

SAN DIEGO, Sept. 01, 2026 /CourierPR/ -- AnaptysBio, Inc., a company managing financial collaborations for its drugs Jemperli and imsidolimab, has announced that its Chief Financial Officer, Chris Murphy, will present at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026. The presentation is set to begin at 3:30 PM Eastern Time.

Attendees and investors will have the opportunity to tune in live via webcast, accessible through the investor section of AnaptysBio's website at [the link provided was omitted as per instructions]. A recording of the presentation will be available for at least 30 days post-event for those unable to attend the live session.

During the conference, Murphy is expected to discuss AnaptysBio's strategic partnerships with GlaxoSmithKline (GSK) and Vanda Pharmaceuticals, focusing on the management of financial collaborations for Jemperli and imsidolimab. The company's primary objective is to protect and return value to its shareholders through these arrangements.

For those interested in further information, the webcast can be accessed on the investor relations page of the company’s website.